Fda approves y-mabs' danyelza® (naxitamab-gqgk) for the treatment of neuroblastoma

New york, nov. 25, 2020 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the u.s. food and drug administration (“fda”) has approved danyelza (naxitamab-gqgk) 40mg/10ml. danyelza is indicated, in combination with granulocyte-macrophage colony-stimulating factor (“gm-csf”), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. this indication is approved under accelerated approval regulation based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory trial. danyelza is a humanized, monoclonal antibody that targets the ganglioside gd2, which is highly expressed in various neuroectoderm-derived tumors and sarcomas. danyelza is administered to patients three times in a week in an outpatient setting and the treatment is repeated every four weeks. the product has received priority review, orphan drug, breakthrough therapy, and rare pediatric disease designations from the fda.
YMAB Ratings Summary
YMAB Quant Ranking